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http://dx.doi.org/10.1016/j.jfma.201Tumor-to-tumor metastasis is an uncommon but well-documented phenomenon. We present
a case of a clear cell renal cell carcinoma (RCC) metastasizing to an invasive ductal carcinoma
(IDC) of the breast. A 74-year-old woman with a past history of clear cell RCC status after
radical nephrectomy underwent right modified radical mastectomy for an enlarging breast
mass 3 years after nephrectomy. Histological examination revealed a small focus with distinct
morphological features similar to clear cell RCC encased in the otherwise typical IDC. Immu-
nohistochemical studies showed that this focus was positive for CD10 and vimentin, in contrast
to the surrounding IDC, which was negative for both markers and positive for Her2/neu. Based
on the histological and immunohistochemical features, the patient was diagnosed with metas-
tasis of clear cell RCC to the breast IDC. To the best of our knowledge, this is the first reported
case of a breast neoplasm as the recipient tumor in tumor-to-tumor metastasis.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The phenomenon of tumor-to-tumor metastasis was first
documented in 1902 by Berent.1 Although not as rare as
previously believed, tumor-to-tumor metastasis is still an
uncommon occurrence. Only 165 cases have been reported in
the English-language literature. The most common recipienthave no conflicts of interest
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tw (L.-Y. Lee).
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2.07.022tumor is renal cell carcinoma (RCC, 38.8%), followed by
meningioma (25.4%), and the most frequent donor tumor is
lung cancer (55.8%). Breast neoplasms have been reported as
the tumor donor in 21 (12.7%) cases, but they never had been
reported as a recipient site of tumor-to-tumor metastasis.
Here, we report a case of clear cell RCC metastasizing to
invasive ductal carcinoma (IDC) of the breast.
Case report
A 74-year-old woman presented to our outpatient
department with a progressively enlarging nontender right
breast mass. She had a past history of stage III
(pT3pN0cM0) grade 2 clear cell RCC after right radical& Formosan Medical Association. All rights reserved.
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after the nephrectomy, and there was no evidence of
recurrence or metastasis after 1 year follow-up. At this
time, breast sonography revealed a solid mass measuring
3.75 cm  3.72 cm  3.22 cm with an irregular margin at 9
o’clock, 4 cm from the right nipple. Core needle biopsy
revealed ductal carcinoma in situ. At the same time,
a small nodular lesion measuring 2.2 cm in greatest
dimension was found in the right upper lobe of her lung,
which was shown to be metastatic clear cell RCC after
computed tomography-guided biopsy and immunohisto-
chemical confirmation [CD10(þ), vimentin(þ), estrogen
receptor (ER)(), progesterone receptor (PR) (), and
thyroid transcription factor-1()]. No local recurrence at
the previous nephrectomy site was found by imaging. The
patient then underwent modified radical mastectomy for
the breast tumor.
On gross examination, the removed breast tissue
measured 23.0 cm  17.5 cm  4.0 cm. On sectioning,
a single solid and circumscribed mass lesion measuring
3.5 cm  3.5 cm  2.0 cm with a hemorrhagic area was
noted; this lesion had a firm consistency and brownetan
appearance. Microscopically, the tumor was composed of
solid sheets of malignant cells with stromal invasion. More
than 75% of the tumor cells throughout the tumor had
ductal differentiation (score 1). Multiple areas of hemor-
rhage were found, but there was no evidence of necrosis or
calcification. The tumor cells were moderately atypical
(score 2) with a low mitotic rate (score 1). These features
were consistent with a score 4 (1 þ 2 þ 1) grade I IDC. There
was no lymph node metastasis and no evidence of distant
metastasis. A combined pathological and clinical stage IIA,
pT2pN0cM0 tumor was diagnosed.
However, there was a small distinct focus measuring
2 mm  2 mm in dimensions found mostly circumscribed by
the IDC (Fig. 1A). The cells composing the focus were
arranged in a small nest pattern with delicate fibrovascular
septa. The cells exhibited clear cytoplasm with moderate
nuclear atypia and conspicuous nucleoli. When encoun-
tering a clear cell tumor in the breast, differential diag-
noses from primary breast tumors to metastasis from
nonmammary malignant neoplasms should be considered
(Table 1). Of all these differentials, clear cell RCC was firstFigure 1 (A) A low-power view of the breast tumor showing a
entirely encased by the typical invasive ductal carcinoma. Original
clear cell RCC in 2006 in the same patient shown in this figure, stri
200, H&E. H&E Z hematoxylin and eosin; RCC Z renal cell carcconsidered according to the patient’s history and the
striking morphological similarities upon hematoxylin and
eosin staining (Fig. 2A). Immunohistochemistry showed that
this distinct focus was positive for CD10 and vimentin but
negative for ER, PR and Her2/neu. In contrast, tumor cells
within the IDC region were negative for CD10, vimentin and
ER, but they were focally positive for PR and equivocally
positive (2þ) for Her2/neu (Fig. 2BeD). Primary breast
tumors of ductal differentiation were generally excluded
based on the triple negative for ER, PR and Her2/neu, and
with positive staining for CD10 and vimentin. The possibil-
ities of adenomyoepithelioma and metastatic malignant
lymphoma were further eliminated by negative staining for
myoepithelial markers (calponin and smooth muscle actin),
and melanocytic marker (HMB-45). It is worth noting that
although S-100 protein is a sensitive marker for detecting
melanoma, it is also positive in 69% and 70% of primary and
metastatic clear cell RCC, respectively.2 Thus, S-100
protein positivity alone, without other supportive evidence,
has no benefit in differential metastatic clear cell RCC and
metastatic melanoma. Based on the histological and
immunohistochemical results noted above, the patient was
diagnosed with metastatic clear cell RCC to IDC of the
breast.Discussion
The diagnosis of tumor-to-tumor metastasis requires the
fulfillment of criteria originally described in 1968 by
Campbell et al.3 First, the patient must have at least two
different tumors, and the recipient tumor must be a true
neoplasm. Second, the metastatic neoplasm must be a true
metastasis, not a contiguous growth such as a “collision
tumor” or an embolism. Third, cases should be excluded if
tumors metastasize to the lymphatic system that had con-
tained a primary lymphatic malignancy. In 1984, Pam-
phlett4 established three additional criteria: (1) the
metastatic nidus must be at least partially enclosed by
a rim of histologically distinct primary tumor tissue; (2) the
existence of the primary carcinoma must be proven; and (3)
the metastatic tumor must be compatible with the primary
carcinoma by morphological or immunohistochemicalfocus morphologically similar to clear cell RCC (arrow) almost
magnification 20, H&E. (B) Comparing Fig. 2A with the grade II
king morphological similarity is evident. Original magnification
inoma.
Table 1 Differential diagnoses of clear cell tumors of the
breast.
Primary breast tumor
Breast tumors of ductal differentiation
Glycogen-rich clear cell carcinoma
Lipid-rich carcinoma
Histiocytoid lobular carcinoma
Apocrine carcinoma
Secretory carcinoma
Breast tumors of myoepithelial differentiation
Adenomyoepithelioma
Nonmammary malignant neoplasms
Metastatic clear cell renal cell carcinoma
Metastatic malignant melanoma
Metastatic prostatic carcinoma
Tumor-to-tumor metastasis 135means. Our case met all of the above criteria; thus, it can
be considered a true tumor-to-tumor metastasis.
Two theories are proposed to explain the pathophysi-
ology of tumor-to-tumor metastasis.5 Based on the ideas
first described by Sir Steven Paget in 1889, the “seed and
soil” theory proposes that metastatic tumor cells (seeds)
attain successful growth and propagation in a hospitable
environment (soil), such as tumors with a low metabolic
rate and high collagen and lipid content. The “mechanical”
theory suggested by Ewing in 1928 proposes that theFigure 2 (A) A high-power view showing the distinct focus on the
arranged in nests with delicate fibrovascular septa. (BeD) Immun
CD10(þ), vimentin(þ), and Her2/neu(). In contrast, invasive ducta
Original magnification 200, hematoxylin and eosin (A), CD10 (B),recipient tumors may be particularly susceptible to
metastases because of high blood flow, highly vascular
architecture, and anatomical location. In these two
models, RCC would be a preferential site of tumor-to-tumor
metastasis, and clinical findings suggest that RCC accounts
for about half of the cases.6 Meningioma as a usually slowly
growing benign neoplasm located in the fertile central
nervous system, providing longer time for seeding and
a nourish environment, is the second most common recip-
ient site of tumor-to-tumor metastasis.6 We used the
keyword “tumor-to-tumor metastatsis” in PubMed to
perform a literature review of English-language publica-
tions and their references. Table 2 shows the current
numbers of cases and distribution of donor/recipient in
tumor-to-tumor metastasis.
The breast, however, is neither an anatomical location
with rich blood flow nor a fertile “soil” with good nutri-
tional supplies. These characteristics might explain why
the breast is an uncommon site of tumor metastasis.
Metastasis to the breast accounts for only 0.5e1.3% of all
malignant mammary tumors in clinical reports.7 Although
metastases are present in approximately 30% of all
patients diagnosed with RCC,8 only 18 cases of breast
metastases of primary renal tumors have been
reported,7e14 which represent only 3% of all extra-
mammary tumors metastasizing to the breast.9 There are
no reports of a breast neoplasm serving as a recipient in
tumor-to-tumor metastasis.
Although the present patient’s history of clear cell RCC
and the striking dimorphic features prompted accurateright composed by cells with clear cytoplasm and nuclear atypia
ohistochemistry of the renal cell carcinoma-like focus showed
l carcinoma showed CD10(), vimentin(), and Her2/neu(2þ).
vimentin (C), Her2/neu (D).
Table 2 Recipient and donor proportions in tumor-to-tumor metastases.
Recipient tumor No. of cases % Donor tumor No. of cases %
Renal cell carcinoma 64/165 38.8 Lung cancer 92/165 55.8
Meningioma 42/165 25.4 Breast cancer 21/165 12.7
Thyroid neoplasms 14/165 8.5 Renal cell carcinoma 15/165 9.1
Others 45/165 27.3 Others 37/165 22.4
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metastatic neoplasms involving otherwise normal breast
tissue. There have been several reported cases initially
diagnosed as primary breast tumors that were later shown
to be metastatic neoplasms from extramammary origins
such as clear cell RCC,10 papillary RCC, and ovarian serous
adenocarcinoma.11 No reliable clinical features distinguish
a metastatic breast lesion from primary breast cancer.8 A
history of other primary malignancies may be an important
clue. However, one must keep in mind that in 20e40% of
cases, breast metastases are the initial presentation of
extramammary malignancies metastasizing to the breast.11
In suspicious or difficult cases, ancillary testing such as
immunohistochemical studies should be performed in
addition to routine histological examination. It is important
to differentiate metastatic tumors from primary breast
cancer because the metastatic tumors can represent the
first presentation of a previously unrevealed malignancy.
The subsequent treatment and/or clinical course may be
different from that for a primary breast neoplasm.12 The
presence of metastatic carcinoma to the breast is an indi-
cation of advanced disease and has a poor prognosis.11 Over
half of the patients presented with additional systemic
metastases, and the median survival was 10 months.15
Three factors determine the survival: patients who were
in otherwise disease-free status, patient who had under-
gone mastectomy as part of the treatment, and patients
with neuroendocrine primary tumors have better prog-
nosis.15 For our patient, mastectomy provided not only the
treatment of her primary breast cancer but also might have
aided her chance of survival. She is currently alive 12
months after discovery of the metastasis with the use of
tamoxifen and interferon therapy.
In summary, extramammary neoplasm metastasizing to
the otherwise normal breast is uncommon, and neoplasm of
breast as a recipient of tumor-to-tumor metastasis has not
been described previously. We report a case of IDC of the
breast as the host of a clear cell RCC. Although tumor-to-
tumor metastasis is an infrequent event, the incidence of
this phenomenon may increase because cancer patients
have improved prognoses and survival times. Identifying
this phenomenon is crucial because it may significantly
affect further evaluation, treatment, and prognosis.References
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